01 December 2018

How Does an Anti-CTLA-4 Antibody Promote Cancer Immunity?

Authors: Liu Y, Zheng P.
Citation: Trends Immunol. 2018 Dec;39(12):953-956. doi: 10.1016/
Products: ONC-392

Rate this item
(0 votes)

Anti-CTLA-4 antibodies can induce lasting protection for some melanoma patients. However, their therapeutic potential is limited by significant immunotherapy-related adverse effects (irAE). Here, we argue that the therapeutic effect may be based on an agonist activity that is fundamentally distinct, and can be therapeutically differentiated, from the antagonist activity responsible for irAE.

Last modified on 31 October 2020

About Us

Based in Rockville, Maryland, OncoImmune is a
privately-held, clinical-stage biopharmaceutical
company that is actively engaged in the discovery
and development of biopharmaceuticals for the
treatment of cancer and autoimmune disease.

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.